© Reuters. FILE PHOTO: A logo of pharmaceutical and chemical group Merck KGaA is pictured in Darmstadt, Germany January 28, 2016. REUTERS / Ralph Orlowski / File Photo
By Ludwig Burger
FRANKFURT (Reuters) – Germany’s Merck KGaA raised its full-year profit forecast on Wednesday, citing a very good performance from its Life Science unit, which supplies materials and equipment to COVID-19 vaccine makers and other drug manufacturers.
The diversified group said in an unscheduled statement that it now expects 2021 earnings before interest, taxes, depreciation and amortization (EBITDA), adjusted for special items, to reach € 6 billion to € 6.3 billion. (7 to 7.3 billion dollars), against 5.2 billion in 2020.
It previously targeted 5.6 billion to 6 billion euros.
Third-quarter adjusted EBITDA fell to 1.55 billion euros, from 1.7 billion a year earlier, but topped the analyst consensus of 1.52 billion published on the Merck website.
Merck said it will release detailed results as scheduled on November 11.
($ 1 = € 0.8633)
Fusion media or anyone involved with Fusion Media will accept no responsibility for any loss or damage resulting from reliance on any information, including data, quotes, graphics and buy / sell signals contained in this website. Please be fully informed about the risks and costs associated with trading in the financial markets, it is one of the riskiest forms of investing possible.